Q (sonnet): Are TP53 mutations clinically actionable?

═ answer (success)
I can help you visualize TP53 mutation data across cBioPortal studies, but I can't determine clinical actionability for you — that's a clinical/therapeutic judgment, not something the database records.

A few notes to keep this grounded:

- **cBioPortal does not store actionability determinations.** It stores mutation calls, frequencies, and (where annotated) OncoKB driver/oncogenicity flags — it does not store treatment-eligibility or actionability status per se.
- **General background** (not from cBioPortal data, for context only): TP53 is one of the most frequently altered tumor suppressor genes across cancers, but it is generally considered difficult to target therapeutically directly — unlike genes such as EGFR or BRAF where specific inhibitors exist, there is no FDA-approved TP53-targeted therapy in routine clinical use as of my knowledge cutoff. Some experimental agents (e.g., reactivating mutant p53) exist in trials, but I want to be clear this is general knowledge, not a finding from cBioPortal, and it is not clinical advice.
- If you're asking because you're evaluating a specific patient or treatment decision:

> I can help you visualize the relevant data in cBioPortal, but this is for research purposes only. I cannot offer clinical advice or prognosis.

For actionability specifically, the appropriate resource is **OncoKB** (oncokb.org), which curates gene- and variant-level actionability levels (Level 1–4, R1–R2) tied to FDA approvals and clinical guidelines — that's a distinct, curated resource from the raw mutation calls in cBioPortal.

If you'd like, I can instead show you:
- TP53 mutation frequency and variant spectrum in a specific study or cancer type
- Which TP53 variants are annotated as oncogenic/driver in cBioPortal's OncoKB integration for a given cohort
- An OncoPrint of TP53 alterations alongside co-occurring/mutually exclusive genes

Let me know which of these you'd like, and in which study or cancer type.